ENTA — Enanta Pharmaceuticals, Inc.

ENTA closed at $12.18 (+1.50%) on Oct 27, 2026. Active shelf registration (S-3, Feb 2026). Float: 27.5M shares. Latest SEC filing: 8-K on Oct 28, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for ENTA in the TickerWise workspace.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 131
• Website: https://www.enanta.com

Latest SEC filings for ENTA

• 2026-10-288-K
• 2026-08-14SCHEDULE 13G/A
• 2026-07-02424B5
• 2026-05-13S-8
• 2026-05-1310-Q
• 2026-05-118-K
• 2026-03-26SCHEDULE 13G/A
• 2026-03-268-K
• 2026-03-128-K
• 2026-02-1110-Q

Latest ENTA news

• 2026-10-13Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.